Down 56.67% KETA.CN TripSitter (CNQ) Feb 18 2026 Market Hours: watch catalysts

KETA.CN stock dropped 56.67% in market hours on 18 Feb 2026, closing at CAD 0.065 after a wide intraday range between CAD 0.055 and CAD 0.10. Volume spiked to 155,010 shares versus an average of 3,644, sending a clear liquidity signal. The move followed weak micro-cap fundamentals, a negative company rating and a surge in selling interest that outpaced sector flows. We break down what changed, how valuation and technicals look, and where analysts see catalysts for any recovery.

KETA.CN stock intraday move and liquidity

The main fact is the price collapse to CAD 0.065, down 56.67% from the prior close of CAD 0.15. One clear driver was heavy trading: volume reached 155,010 versus avg volume 3,644, a relative volume of 42.54. That level shows forced or panic selling rather than routine rebalancing. Intraday range: low CAD 0.055, high CAD 0.10, which signals high volatility and low depth in Canadian micro-cap listings.

Drivers behind the drop: news, ratings and sector context

TripSitter Clinic Ltd. (KETA.CN) operates a tele-health ketamine platform in the United States with limited reported revenues and negative EPS of -0.04. The stock carries a recent third-party company rating of C- with a Strong Sell recommendation dated 13 Feb 2026, adding selling pressure. Healthcare sector performance was weaker on the day, with the broader group down 3.52% 1D, which likely amplified momentum selling in small healthcare names.

KETA.CN analysis: valuation and financial snapshot

KETA.CN’s market cap sits at CAD 432,781 with 6,658,174 shares outstanding. Key ratios show stress: reported PE is -1.62 and book value per share is -0.12. Cash per share is minimal at 0.00009, and the current ratio is effectively 0.00, highlighting liquidity risk. Price averages are 50-day CAD 0.11 and 200-day CAD 0.08, confirming the recent price is below medium-term trend levels.

Technicals and trading picture for KETA.CN stock

Momentum and trend indicators show a strong downtrend: ADX is 100.00, RSI reads 0.00 and MACD is marginally negative. Bollinger Bands are Upper 0.09 / Middle 0.06 / Lower 0.03, so the price sits near the lower band. The technicals signal continued directional selling until evidence of buying appears. Traders should note the extreme relative volume and thin order book typical for micro-cap names on CNQ.

Meyka AI rates and forecast for KETA.CN

Meyka AI rates KETA.CN with a score out of 100: 63.46 / Grade B / HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company has mixed signals: the proprietary grade is neutral while third-party firm ratings flagged a Strong Sell. Meyka AI’s forecast model projects a quarterly price of CAD 0.10 and a monthly target of CAD 0.35. Versus the current CAD 0.065, the quarterly target implies an upside of 53.85%, and the monthly model implies 438.46%. Forecasts are model-based projections and not guarantees.

Risks, catalysts and what to watch next

Primary risks are low liquidity, weak balance-sheet ratios and negative EPS. Catalysts that could stabilize the stock include clearer revenue reports, a credible financing update, or regulatory progress in the medical ketamine space. Watch daily volume, any management statements, and guideline changes in tele-health policy. Also monitor sector flows: continued sector weakness may suppress any recovery attempt in small healthcare stocks like TripSitter Clinic Ltd.

Final Thoughts

KETA.CN stock’s sharp intraday fall to CAD 0.065 on 18 Feb 2026 reflects thin liquidity, a negative third-party firm rating, and micro-cap volatility rather than a single fundamental surprise. The balance sheet and key ratios show material stress: negative EPS -0.04, limited cash per share and a negative book value. Meyka AI’s model points to a quarterly projection of CAD 0.10 and a monthly projection of CAD 0.35, implying +53.85% and +438.46% relative moves if those levels were reached from CAD 0.065. Those figures are model-based and subject to substantial uncertainty. For active traders the intraday volume spike creates trading opportunities but also very high risk. For longer-term investors, the stock needs clear operational improvements and financing clarity before the grade shifts from Hold toward Buy. Use stop-loss discipline and size positions to reflect micro-cap risk. For company filings and platform details visit TripSitter’s site and our Meyka stock page for live updates and charting tools.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.